Fusion protein technologies for biopharmaceuticals : applications and challenges / edited by Stefan R. Schmidt.
Contributor(s): Schmidt, Stefan R.
Material type:
BookPublisher: Hoboken, New Jersey : John Wiley & Sons, ©2013Description: 1 online resource.Content type: text Media type: computer Carrier type: online resourceISBN: 9781118354582; 1118354583; 9781118354575; 1118354575; 9781118354568; 1118354567; 9781118354599; 1118354591; 9781299241954; 1299241956.Subject(s): Biopharmaceutics | Pharmaceutical biotechnology | Drug carriers | Immunotoxins -- Therapeutic use | Protein engineering | Recombinant fusion proteins -- Therapeutic use | MEDICAL -- Pharmacology | Biopharmaceutics | Pharmaceutical biotechnology | Recombinant Fusion Proteins -- therapeutic use | Drug Carriers | Immunotoxins -- pharmacokinetics | Immunotoxins -- therapeutic use | Protein Engineering | Recombinant Fusion Proteins -- pharmacokineticsGenre/Form: Electronic books. | Electronic books.Additional physical formats: Print version:: Fusion protein technologies for biopharmaceuticals.DDC classification: 615.7 Online resources: Wiley Online Library Includes bibliographical references and index.
Print version record and CIP data provided by publisher.
pt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm.
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei.
There are no comments for this item.